Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Tens of thousands of Kaiser Permanente workers in California and Hawaii have gone on strike, demanding safer staffing levels ...

Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they're vital for ...

Nearly half of healthcare executives plan to leave their organizations within the next year, according to a recent survey. Such significant turnover puts healthcare organizations at risk for ...

In the five years since Italy-based Chiesi Group established its rare disease division in Boston, the unit has landed regulatory approvals worldwide for 10 therapies — all small molecules and ...

Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in ...

Experts warn that the Trump administration’s new $100,000 fee for H-1B visa applications could worsen healthcare’s workforce ...

Healthcare has been moving steadily out of the clinic and into the home. McKinsey estimates that as much as $265 billion in care (nearly a quarter of all Medicare spending) could shift from facilities ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

Talkspace, a virtual mental health company, announced on Monday that it has acquired Wisdo Health, a platform for social health and peer support. New York City-based Talkspace offers virtual therapy, ...